Achillion-Logo-150 (4).jpg
Achillion Reports Second Quarter 2016 Financial Results
August 04, 2016 16:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second...
Akari Logo (1).jpg
Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria
July 13, 2016 07:00 ET | Akari Therapeutics, Plc
NEW YORK and LONDON, July 13, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the approval by the UK...
Akari Logo (1).jpg
Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria
July 12, 2016 07:00 ET | Akari Therapeutics, Plc
NEW YORK and LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines...
Achillion-Logo-150 (4).jpg
Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
June 10, 2016 03:30 ET | Achillion Pharmaceuticals, Inc.
-  Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471  - -  Results support initiation...
Akari Logo (1).jpg
Akari Therapeutics to Present at the Jefferies 2016 Healthcare Conference
May 26, 2016 07:00 ET | Akari Therapeutics Plc
NEW YORK and LONDON, May 26, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced that Gur Roshwalb, MD, Chief...
Akari Logo (1).jpg
Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barré Syndrome
May 23, 2016 07:10 ET | Akari Therapeutics Plc
NEW YORK and LONDON, May 23, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines...
Akari Logo (1).jpg
Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated
May 19, 2016 07:30 ET | Akari Therapeutics Plc
NEW YORK and LONDON, May 19, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that data on Coversin...
Achillion-Logo-150 (4).jpg
Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
May 19, 2016 06:05 ET | Achillion Pharmaceuticals, Inc.
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers - NEW HAVEN,...
Achillion-Logo-150 (4).jpg
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
May 03, 2016 06:05 ET | Achillion Pharmaceuticals, Inc.
-  Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 – ...
Akari Logo (1).jpg
Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin
March 31, 2016 16:03 ET | Akari Therapeutics Plc
NEW YORK and LONDON, March 31, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today preliminary results from...